Filing Flows › GeneDx Holdings (WGS) › Q2 2026 › vs Q2 2025
GeneDx Holdings (WGS) Q2 2026 vs Q2 2025 (year over year)
GeneDx Holdings's revenue rose $11.7M (+11%) from $103M in Q2 2025 to $114M in Q2 2026. The biggest changes: Diagnostic Test +$11.8M (+12%); Other revenue −$38K (-1%).
GeneDx Holdings, Q2 2026: revenue $114M (+11% year over year), operating margin -15.3%, net loss $17.7M, operating cash flow −$29.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Patients with third-party insurance | $94.7M | $81.1M | $13.6M | +17% |
| Institutional customers | $16.1M | $18.7M | −$2.5M | -14% |
| Self-pay patients | $1.0M | $339K | $703K | +207% |
| Diagnostic Test | $112M | $100M | $11.8M | +12% |
| Other revenue | $2.6M | $2.6M | −$38K | -1% |
| Revenue | $114M | $103M | $11.7M | +11% |
| Income tax benefit | $518K | $246K | $272K | +111% |
| Net loss | $17.7M | −$10.8M | $28.5M | — |
| Costs & expenses | $133M | $105M | $28.2M | +27% |
| Operating costs | $132M | $93.7M | $38.2M | +41% |
| Interest & other, net | $803K | −$1.6M | $2.4M | — |
| Cost of revenue | $36.2M | $31.8M | $4.4M | +14% |
| Research & development | $19.7M | $15.1M | $4.6M | +30% |
| Operating cash sources | $42.0M | $3.6M | $38.5M | 12× |
| Depreciation & amortization | $6.7M | $6.2M | $523K | +8% |
| Share-based compensation | $6.3M | $7.8M | −$1.5M | -19% |
| Cash used in operations | $29.0M | −$10.4M | $39.4M | — |
| Net loss absorbed | $17.7M | −$10.8M | $28.5M | — |
| Working capital & other | $24.3M | $14.4M | $9.9M | +69% |
Questions
How much did GeneDx Holdings's revenue grow year over year in Q2 2026?
GeneDx Holdings's revenue rose $11.7M (+11%) from $103M in Q2 2025 to $114M in Q2 2026.
What drove GeneDx Holdings's revenue change in Q2 2026?
Diagnostic Test +$11.8M (+12%); Other revenue −$38K (-1%).